MGMT
AstraZeneca's ATM Inhibitor, Radiation Show Encouraging Signals in Two Early Brain Cancer Trials
Premium
At AACR, researchers suggested AZD1390 could penetrate the brain and promote DNA damage repair in MGMT unmethylated glioblastoma.
The company is exploring VAL-083 across the spectrum of newly diagnosed and recurrent unmethylated and methylated MGMT glioblastoma.
MimiVax to Begin Phase II Study of Immunotherapy Vaccine in Glioblastoma
The study will explore molecular predictors of response to MiMiVax's SurVaxM, including MGMT methylation status, IDH1 mutation, and survivin-specific responses.
Denovo Begins Phase III Glioblastoma Trial of Enzastaurin
The firm is evaluating enzastaurin plus chemo and radiation in glioblastoma patients with a biomarker, dubbed de novo genomic marker 1.
Kazia Therapeutics, Kintara Therapeutics Begin Trials in Glioblastoma Platform Study
The companies' treatments, paxalisib and VAL-083, are being studied in the GBM AGILE trial sponsored by the Global Coalition for Adaptive Research.